Answers are grounded in this paper and cite their sources.
Ontology development aims to enhance representation of therapeutic antibodies, indicating improved data management and analysis capabilities.
Introduction/Background: Therapeutic antibodies play critical roles in treating cancer, autoimmune disorders, infectious diseases, and many other conditions, ranking among the fastestgrowing and highest-revenue drug classes today. Objective: To better represent, manage, and analyze the rapidly increasing volume of data, the Therapeutic Antibodies Ontology (TAON) was developed to formally capture and integrate knowledge about therapeutic antibodies and their corresponding drug products, targets, and mechanisms of action. Methods: TAON was developed by extending the core upper-level framework of the Basic Formal Ontology (BFO) and strategically reusing terms from authoritative, community-endorsed ontologies to minimize redundancy and ensure interoperability. Results: TAON comprises 10,281 is-a relations, 46 object properties, 12 data properties, and 108 annotation properties, forming a robust logico-structural framework of 3,558 classes constrained by 57,517 axioms. Evaluation results confirm that TAON not only passes consistency testing but also demonstrates high semantic richness, meeting the criteria for a deep ontology. Moreover, two validated use cases demonstrate its capability to model and explore complex relationships among therapeutic antibodies, targets, and clinical indications. Discussion: TAON provides a comprehensive three-layer antibody-drug-indication hierarchy and an ontology for therapeutic antibodies that is machine-interpretable, portable, and integrable, enabling data sharing and cross-dataset analysis. The future version will integrate additional therapeutic antibody- related knowledge and update the evaluation framework. Conclusion: In this study, TAON, the first ontology dedicated to therapeutic antibodies, was developed to provide a comprehensive representation of therapeutic antibody knowledge. Moving forward, TAON will focus on enabling systematic knowledge representation, seamless integration, and AIassisted querying to advance the therapeutic antibody research landscape.
No takes yet. Share an insight, caveat, or question.
Gou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: